Gordon Dunn
Equibles does not estimate personal net worth.
About Gordon Dunn
Earlier roles on record: CFO at Quoin Pharmaceuticals Ltd. (QNRX) until August 15, 2025. Quoin Pharmaceuticals Ltd. reported in an 8-K filed August 27, 2025 that Gordon Dunn was terminated as Chief Financial Officer, effective August 15, 2025. The proxy statement of Quoin Pharmaceuticals Ltd. reports total compensation of $656,632 for Gordon Dunn in fiscal 2024, including a base salary of $433,620. Disclosed compensation is on record for 3 fiscal years. Gordon Dunn has spoken on 5 earnings calls across 1 company, most recently for Quoin Pharmaceuticals Ltd. on March 14, 2024. The companies whose calls Gordon Dunn spoke on are classified in the Healthcare sector.
“Mr. Dunn's last day as Chief Financial Officer of the Company was August 15, 2025.”
Gordon Dunn on recent calls
“We appreciate you joining us on today's conference call. With me on the call are Dr. Michael Myers, CEO; and Denise Carter, COO. We're pleased to provide an update on our progress for the fourth quarter of 2023 as well as discussing our Q4 and full year 2023 financial results.”
“We appreciate you joining us on today’s conference call. With me on the call are Dr. Michael Myers, CEO, and Denise Carter, COO. We’re pleased to provide an update on our progress for the third quarter of 2023, as well as discussing our Q3 2023 financial results.”
“We appreciate you joining us on today's conference call. With me on the call are Dr. Michael Myers, CEO, and Denise Carter, COO. We're pleased to provide an update of our progress for the second quarter of 2023, as well as discussing our Q2 2023 financial results.”
“We appreciate you joining us on today's conference call. With me on the call are Dr. Michael Myers, CEO; and Denise Carter, COO. We're pleased to provide an update of our progress in the first quarter of 2023, as well as discussing our Q1 2023 financial results.”
“We appreciate you joining us on today's conference call. With me on the call are Dr. Michael Myers, CEO; and Denise Carter, COO. We're pleased to provide an update on our progress throughout the fourth quarter of 2022 and for the year as a whole and discussing Quoin Pharmaceuticals financial results.”
Affiliation history
-
Start not stated–2025-08-15
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Quoin Pharmaceuticals Ltd. (QNRX) | Chief Financial Officer | $433,620 | $656,632 |
| 2023 | Quoin Pharmaceuticals Ltd. (QNRX) | Chief Financial Officer | $394,200 | $775,935 |
| 2022 | Quoin Pharmaceuticals Ltd. (QNRX) | Chief Financial Officer | $360,000 | $1,450,207 |